Lion's Mane for Pets: What We Know from Research

Written by Peter Orpen, Co-Owner & Formulator, Teelixir

If you have an older dog who seems confused, sleeps more than usual, or stares blankly at walls, you may have researched Canine Cognitive Dysfunction — and perhaps stumbled across Lion's Mane mushroom as a potential support. This article explains what the research actually shows, where the evidence is genuinely preliminary, and what responsible use looks like if you and your vet decide to explore it.

Important: This article is for educational purposes only and is not intended to diagnose, treat, cure or prevent any disease in animals or humans. Always consult your veterinarian before giving any supplement to your pet. Individual results may vary.

Why Pet Owners Are Asking About Lion's Mane

Senior pets — particularly dogs — can develop a condition called Canine Cognitive Dysfunction (CCD), sometimes informally called "dog dementia." Dogs with CCD may become disoriented in familiar environments, forget house-training, lose interest in play, sleep during the day and pace at night, or fail to recognise familiar people. Estimates suggest CCD affects roughly 14–35% of dogs over the age of eight, with prevalence increasing sharply in dogs over twelve.

The parallels with human Alzheimer's disease are striking. Both involve amyloid-beta plaque accumulation, oxidative stress, and disrupted neural signalling. Because Lion's Mane (Hericium erinaceus) has been studied for its effects on nerve growth factor (NGF) — a protein critical to neuron survival and function — some pet owners and integrative vets have begun considering it for ageing dogs. But the evidence trail matters here, and it is important to trace it carefully.

The NGF Pathway: What Human Research Shows

Lion's Mane contains two families of bioactive compounds — hericenones (from the fruiting body) and erinacines (from the mycelium) — that have been shown in laboratory settings to stimulate NGF synthesis. NGF is essential for the growth, maintenance, and survival of neurons, particularly in the peripheral nervous system and in brain regions associated with memory and learning.

In humans, the most cited clinical evidence comes from a small but rigorous randomised controlled trial (RCT): PMID: 18844328 — Mori et al. (2009) — a double-blind, placebo-controlled study involving n = 30 older adults with mild cognitive impairment. Participants received 750 mg of dried Lion's Mane fruiting body three times daily (3 g/day total) for 16 weeks. Cognitive scores improved significantly in the Lion's Mane group compared to placebo, with no serious adverse events reported. Importantly, scores declined again four weeks after supplementation ceased, suggesting the effect was dependent on continued use rather than a permanent structural change.

A more recent safety review (PMID: 40959699, published 2024) assessed the human safety profile of Lion's Mane across multiple trials. The overall conclusion was that Lion's Mane is generally well tolerated in human studies at therapeutic doses, with the most commonly reported adverse events being mild gastrointestinal discomfort in a small proportion of participants. This is human safety data — it cannot be directly applied to animals, but it provides a reference point for the compound's tolerability in mammals generally.

A broader review of the NGF pathway (PMID: 34865649) contextualises these findings, noting that both hericenones and erinacines are small enough to cross the blood-brain barrier in rodent models and have shown neuroprotective activity in multiple animal studies. This review explicitly includes animal model data and notes that mammalian NGF pathways share significant structural homology — meaning the biological logic that applies to rodents and humans also applies, in principle, to dogs and cats. In principle. No veterinary trial has tested this assumption.

For a full breakdown of the human evidence, see our complete Lion's Mane evidence guide.

Animal Model Data: What Rodent Studies Show

Note: The studies below are rodent studies — mouse and rat models. They do not constitute evidence of effect in dogs or cats. Animal data provides mechanistic plausibility, not clinical proof.

One frequently cited mouse study (PMID: 20834180) examined the effects of erinacine A — one of Lion's Mane's key bioactive compounds — on depressive-like behaviour in rodents. Using the forced swim test (a standard preclinical model), researchers observed statistically significant reductions in immobility time in the erinacine A group compared to controls. The proposed mechanism involved regulation of serotonergic pathways and NGF expression in the hippocampus. This is animal data only and should not be interpreted as evidence that Lion's Mane addresses depression or anxiety in pets.

A separate mouse study (PMID: 29677563) investigated the effect of Lion's Mane polysaccharides in a chemically induced colitis model. The polysaccharide fraction reduced inflammatory markers including TNF-alpha and IL-6, and reduced damage to the intestinal mucosa. Again, this is a mouse study using a specific experimental disease model. The relevance to pet gut health is speculative — but it does suggest that the anti-inflammatory properties identified in rodents are worth noting as a potential secondary mechanism of interest.

Across multiple preclinical studies, Lion's Mane has shown: NGF stimulation in neuronal cell lines, neuroprotective effects in amyloid-beta mouse models, reduced oxidative stress markers in aged rodents, and anti-inflammatory activity in gut models. None of these studies involved dogs or cats, and none used doses that have been validated for companion animals.

Canine Cognitive Dysfunction: The Condition Explained

CCD is a neurodegenerative condition in older dogs that shares several pathological features with Alzheimer's disease in humans. Key characteristics include:

• Amyloid-beta accumulation — the same protein plaques implicated in human Alzheimer's disease accumulate in the canine brain, particularly in the prefrontal cortex and hippocampus
• Oxidative damage — elevated reactive oxygen species and reduced antioxidant activity in neural tissue
• Reduced cerebral blood flow — associated with cognitive decline and disorientation
• Cholinergic deficit — reduced acetylcholine signalling, paralleling human cognitive decline

Dogs have NGF. The protein performs the same biological role in the canine nervous system as it does in human and rodent neural tissue. This is the basis of the theoretical interest in Lion's Mane for CCD — if NGF supports neuron survival and function, and Lion's Mane stimulates NGF, the reasoning follows. But reasoning is not evidence. No controlled veterinary trial has been published to date testing Lion's Mane in dogs with CCD or any other canine neurological condition.

Currently approved veterinary interventions for CCD include selegiline (a monoamine oxidase inhibitor), dietary modifications (diets enriched with antioxidants and omega-3 fatty acids), and environmental enrichment. These have peer-reviewed veterinary evidence behind them. Lion's Mane does not — at least not yet.

What We Don't Know: The Evidence Gaps

To be direct about the limitations — and this matters if you are considering this for your pet:

• No veterinary trial exists. Not a single published RCT, observational study, or case series has examined Lion's Mane in dogs or cats. The evidence gap is complete.
• No dosing data for pets. Human trials have used doses of 750 mg three times daily (3 g/day) for cognitive effects. Rodent studies have used weight-adjusted doses that do not translate directly to canine dosing because metabolism, gut flora, and absorption differ significantly between species.
• No pet safety data. The safety data cited above (PMID: 40959699) applies to humans. Dogs and cats metabolise compounds differently — some substances safe for humans are toxic to animals (e.g. xylitol, certain essential oils). While Lion's Mane has not been flagged as known dangerous in dogs, the absence of evidence of harm is not the same as evidence of safety.
• Small sample sizes in human studies. The pivotal human RCT had a small sample (n = 30). Even the best-available human evidence is preliminary.
• Species-specific pharmacokinetics unknown. How a dog absorbs, distributes, metabolises, and excretes Lion's Mane bioactives is entirely unstudied.

Any claim that Lion's Mane resolves, addresses, or eliminates Canine Cognitive Dysfunction would be unsupported by evidence. That is not what this article is suggesting. What can be said honestly is: the mechanistic rationale is plausible, the compound appears safe in humans, animal models show relevant biological activity, and some pet owners and integrative vets are exploring it — while acknowledging the uncertainty.

Practical Considerations If You Choose to Explore It

If, after discussing with your veterinarian, you decide to explore Lion's Mane for your senior dog, the following principles apply based on general supplement safety reasoning — not pet-specific evidence:

• Consult your vet first. This is not optional. Your vet can assess whether your dog has any conditions or is taking medications that might interact with a new supplement. Selegiline, for instance, affects serotonergic pathways — and Lion's Mane has shown serotonin-related activity in rodent models.
• Start very small. In the absence of dosing data, many integrative vets who do explore mushroom supplements in dogs start at a fraction of a human dose, adjusted very roughly by body weight, and increase slowly while monitoring for any adverse reaction.
• Choose a clean product. Fruiting body extract, not mycelium-on-grain, and preferably dual-extracted to preserve both water-soluble beta-glucans and fat-soluble hericenones. A certified organic product reduces the risk of pesticide contamination — relevant for any animal with smaller body mass and potentially greater relative sensitivity to contaminants.
• Monitor closely. Watch for gastrointestinal upset (the most commonly reported issue in humans), changes in appetite, lethargy, or any unusual behaviour. If anything concerns you, stop and consult your vet.
• Manage expectations. This is exploratory, not therapeutic. The honest expectation is that you are trying something with biological plausibility but no proven effect. Individual results may vary.

For background on how Lion's Mane is used by humans, including how to use Lion's Mane powder in practice, see our how to use Lion's Mane guide. And for a thorough look at human safety data, our Lion's Mane safety review covers reported adverse events and contraindications.

Frequently Asked Questions

Author: Peter Orpen, Co-Owner & Formulator, Teelixir